A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea])

Bibliography

• Global report 2010. Geneva: UNAIDS, 2010. Available from: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf
   Google Scholar
• Virginia Department of Health. The impact of HIV/AIDS among black women in Virginia. VDH: Division of Disease Prevention (HIV, STD, TB RX) August 2006
   Google Scholar
• Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008;8:447-57
   PubMed Web of Science ®Google Scholar
• Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009;6:20-8
   PubMedGoogle Scholar
• Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464:217-23
   PubMed Web of Science ®Google Scholar
• Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011;62:127-39
   PubMed Web of Science ®Google Scholar
• Uckun FM, D'Cruz OJ. Prophylactic contraceptives for HIV/AIDS. Hum Reprod Update 1999;5:506-14
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006;57:411-23
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Shattock R, Moore JP. Antiretroviral drug based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008;59:455-71
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Microbicides for multidrug-resistant and multitropic HIV-1. Curr Opin Investig Drugs 2008;9:152-69
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74
   PubMed Web of Science ®Google Scholar
• Jespers VA, Van Roey JM, Beets GI, Buve AM. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 2007;44:154-8
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004;10:315-36
   PubMed Web of Science ®Google Scholar
• Van Damme L, Chandeying V, Ramjee G, Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 2000;14:85-8
   PubMed Web of Science ®Google Scholar
• Feldblum PJ, Adeiga A, Bakare R, SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474
   PubMed Web of Science ®Google Scholar
• Halpern V,, Ogunsola F, Obunge O, Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008;3:e3784
   PubMed Web of Science ®Google Scholar
• Roehr B. Microbicide offers no protection against HIV infection. BMJ 2009;339:b5538
   PubMedGoogle Scholar
• Skoler-Karpoff S, Ramjee G, Ahmed K, Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-87
   PubMed Web of Science ®Google Scholar
• Elinder M. Towards a new generation of anti-HIV drugs. Interaction kinetic analysis of enzyme inhibitors using SPR-biosensors. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Science and Technology 834. Uppsala: Acta Universitatis Upsaliensis; 2011. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-152172 p. 66
   Google Scholar
• D'Cruz OJ, Uckun FM. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Enzyme Inhib Med Chem 2006;21:329-50
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 2006;4:329-45
   PubMed Web of Science ®Google Scholar
• Zussman A, Lara L, Lara HH, Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003;17:653-61
   PubMed Web of Science ®Google Scholar
• Barnard J, Borkow G, Parniak MA. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 1997;36:7786-92
   PubMed Web of Science ®Google Scholar
• Borkow G, Barnard J, Nguyen TM, Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997;71:3023-30
   PubMed Web of Science ®Google Scholar
• Borkow G, Salomon H, Wainberg MA, Parniak MA. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retroviruses 2002;18:711-14
   PubMed Web of Science ®Google Scholar
• Hossain MM, Parniak MA. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. J Virol 2006;80:4440-6
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide. Mol Hum Reprod 2005;11:767-77
   PubMed Web of Science ®Google Scholar
• Kenney J, Aravantinou M, Singer R, An antiretroviral/zinc combination gel provides 24 h of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835
   PubMedGoogle Scholar
• Pani A, Musiu C, Loi AG, DABOs as candidates to prevent mucosal HIV transmission. Antivir Chem Chemother 2001;12(Suppl 1):51-9
   PubMedGoogle Scholar
• Cole AM. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006;306:199-230
   PubMed Web of Science ®Google Scholar
• Hickey DK, Patel MV, Fahey JV, Wira CR. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 2011;88:185-94
   PubMed Web of Science ®Google Scholar
• Fichorova RN, Bajpai M, Chandra N, Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004;71:761-9
   PubMed Web of Science ®Google Scholar
• Weber J, Desai K, Darbyshire J; Microbicides Development Programme. The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med 2005;2(e142):392-5
   Google Scholar
• Catalone BJ, Kish-Catalone TM, Neely EB, Comparative safety evaluation of candidate vaginal microbicide C31G. Antimicrob Agents Chemother 2005;49:1509-20
   PubMed Web of Science ®Google Scholar
• Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor-alpha and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86:2336-40
   PubMed Web of Science ®Google Scholar
• Febo IL, Beauchamp B. Prevention overview: role of microbicides in preventing HIV infection. HIV CareLink Newsletter July 13, 2011. Available from: www.FCAETC.org/Newsletter
   Google Scholar
• Mayer KH, Karim SA, Kelly C, Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003;17:321-9
   PubMed Web of Science ®Google Scholar
• Mauck CK, Weiner DH, Creinin MD, A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength Gynol II. Contraception 2004;70:233-40
   PubMed Web of Science ®Google Scholar
• Van der Straten A, Napierala S, Cheng H, A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception 2007;76:389-99
   PubMed Web of Science ®Google Scholar
• Van de Wijgert JH, Braunstein SL, Morar NS, Carraguard vaginal gel safety in HIV-positive women and men in South Africa. J Acquir Immune Defic Syndr 2007;46:538-46
   PubMed Web of Science ®Google Scholar
• Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969;20:85-93
   PubMedGoogle Scholar
• Belec L, Gherardi R, Payan C, Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995;7:568-74
   PubMed Web of Science ®Google Scholar
• Noguchi K, Tsukumi K, Urano T. Qualitative and quantitative differences in normal vaginal flora of conventionally reared mice, rats, hamsters, rabbits, and dogs. Comp Med 2003;53:404-12
   PubMed Web of Science ®Google Scholar
• Stafford MK, Ward H, Flanagan A, Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:327-31
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention, August 4, 2000, posting date. Letter from the Director, National Center for HIV, STD, and TB Prevention. Available from: http://www.cdc.gov/hiv/pubs/mmwr/mmwr11aug00.htm
   Google Scholar
• Wang FX, Xu Y, Sullivan J, IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115:128-37
   PubMed Web of Science ®Google Scholar
• Romano J, Variano B, Coplan P, Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009;25:483-8
   PubMed Web of Science ®Google Scholar
• Mai A, Artico M, Sbardella G, Dihydro(alkylthio)(naphthylmethyl)oxo pyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J Med Chem 1997;40:1447-54
   PubMed Web of Science ®Google Scholar
• Van Herrewege Y, Michiels J, Van Roey J,, In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004;48:337-9
   PubMed Web of Science ®Google Scholar
• Di Fabio S, Van Roey J, Giannini G, Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003;17:1597-604
   PubMed Web of Science ®Google Scholar
• Nel AM, Smythe SC, Habibi S, Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010;55:161-9
   PubMed Web of Science ®Google Scholar
• Selhorst P, Vazquez AC, Terrazas-Aranda K, Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother 2011;55:1403-13
   PubMed Web of Science ®Google Scholar
• Herrera C, Cranage M, McGowan I, Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009;53:1797-807
   PubMed Web of Science ®Google Scholar
• Kenney J, Aravantinou M, Singer R, An antiretroviral/zinc combination gel provides 24 h of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835
   PubMedGoogle Scholar
• Sudbeck EA, Mao C, Vig R, Uckun FM. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1998;42:3225-33
   PubMed Web of Science ®Google Scholar
• Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant HIV. Antivir Chem Chemother 1999;10:233-40
   PubMed Web of Science ®Google Scholar
• Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Rational design of N-[2-(2,5-dimethoxyphenyl ethyl)] -N'-[2-(5-bromopyridyl)]-thiourea (PHI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 1999;9:1593-8
   PubMed Web of Science ®Google Scholar
• Uckun FM, Pendergrass S, Maher D, N'-[2-(2-thiophene)ethyl[-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 1999;9:3411-16
   PubMed Web of Science ®Google Scholar
• Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based drug design of nonnucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol 2000;60:1251-65
   PubMed Web of Science ®Google Scholar
• Bell FW, Cantrell AS, Hogberg M, Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J Med Chem 1995;38:4929-36
   PubMed Web of Science ®Google Scholar
• Alcaro S, Alteri C, Artese A, Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. ChemMedChem 2011;6:2203-13
   PubMed Web of Science ®Google Scholar
• Cantrell AS, Engelhardt P, Hogberg M, Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. J Med Chem 1996;39:4261-74
   PubMed Web of Science ®Google Scholar
• Sudbeck EA, Jennissen JD, Venkatachalam TK, Uckun FM. Inhibitor of HIV-1 reverse transcriptase: N'-(5-bromo-2-pyridyl)-N-[2-(2,5-dimethoxyphenyl)ethyl] thiourea. Acta Crystallogr C 1999;55:2122-4
   PubMed Web of Science ®Google Scholar
• Ren J, Diprose J, Warren J, Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J Biol Chem 2000;275:5633-9
   PubMed Web of Science ®Google Scholar
• de Oliveira CF, Diaz RS, Machado DM, Surveillance of HIV-1 genetic subtypes and diversity in the US blood supply. Transfusion 2000;40:1399-406
   PubMed Web of Science ®Google Scholar
• Wensing AM, van de Vijver DA, Angarano G, Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-66
   PubMed Web of Science ®Google Scholar
• Grant RM, Hecht FM, Warmerdam M, Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-8
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy J-P, Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Balaguera HU, Freedberg KA, Drug-selected resistance mutations and non-B subtypes in antiviral-naive adults with established human immunodeficiency virus infection. J Infect Dis 2003;188:986-91
   PubMed Web of Science ®Google Scholar
• McCutchan FE. Global epidemiology of HIV. J Med Virol 2006;78:S7-S12
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Venkatachalam T. N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity. Arzneimittelforschung 2007;57:278-85
   PubMed Web of Science ®Google Scholar
• Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 2005;57:1692-712
   PubMed Web of Science ®Google Scholar
• Acarturk F. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 2009;3:193-205
   PubMedGoogle Scholar
• Arzhavitna A, Steckel H. Foams for pharmaceutical and cosmetic application. Int J Pharm 2010;394:1-17
   PubMedGoogle Scholar
• D'Cruz OJ, Samuel P, Uckun FM. Conceival, a novel non-contraceptive vaginal vehicle for lipophilic microbicides. AAPS PharmSciTech 2005;6:E56-64
   PubMedGoogle Scholar
• D'Cruz OJ, Samuel P, Uckun FM. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod 2004;71:2037-47
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1. Fertil Steril 2007;88:1197-206
   PubMed Web of Science ®Google Scholar
• Ayehunie S, Cannon C, Larosa K, Development of an in vitro alternative assay method for vaginal irritation. Toxicology 2011;279:130-8
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Erbeck D, Uckun FM. A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicol Pathol 2005;33:465-76
   PubMed Web of Science ®Google Scholar
• Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J Pharm Sci 2008;97:9-21
   PubMed Web of Science ®Google Scholar
• Uckun FM, Tibbles HE, Venkatachalam TK, Erbeck D. In vivo pharmacokinetics, metabolism, toxicity, and anti-HIV activity of N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a potent non-nucleoside inhibitor of HIV reverse transcriptase. Arzneimittelforschung 2007;57:483-96
   PubMed Web of Science ®Google Scholar
• DuMez D, Venkatachalam TK, Uckun FM. Large-scale synthesis of GMP grade N'- [2-(2-thiophene) ethyl]-N'- [2-(5-bromopyridyl)] -thiourea (HI-443), a new anti-HIV drug candidate. Arzneimittelforschung 2007;57:330-8
   PubMed Web of Science ®Google Scholar
• Patterson KB, Prince HA, Kraft E, Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4
   PubMed Web of Science ®Google Scholar
• Johnson TJ, Srinivasan P, Albright TH, Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2011; Epub ahead of print
   Web of Science ®Google Scholar
• Watson Buckheit K, Yang L, Buckheit RW Jr. Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob Agents Chemother 2011;55:5243-54
   PubMed Web of Science ®Google Scholar